Trastuzumab deruxtecan in metastatic HER2+ breast cancer

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancerПодробнее

Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer | Dr. Jitendra PahlajaniПодробнее

Efficacy of trastuzumab deruxtecan in HER2-low metastatic breast cancerПодробнее

Trastuzumab-Deruxtecan: A Game-Changer in HER2-Positive Cancers │ PharmacologyПодробнее

Dr Davis on the Investigation of Neratinib + Trastuzumab Deruxtecan in Advanced HER2+ Solid TumorsПодробнее

Optimizing HER2-Positive Breast Cancer Therapy: Balancing Efficacy and ToxicityПодробнее

Dr Hamilton on Implications of DESTINY-Breast06 on the HER2-Low Breast Cancer ParadigmПодробнее

Antibody-Drug Conjugates into the Management of HR+ and Triple-Negative Metastatic Breast CancerПодробнее

Dr Waks on Key Questions Regarding the First-Line Use of T-DXd in HER2+ Breast CancerПодробнее

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated w...Подробнее

Endometrial Cancer: HER2-Targeted ADCs: A Promising Approach to Address Unmet NeedsПодробнее

Optimal Management of ADC-Related Gastrointestinal AEs in NSCLCПодробнее

ADCs on the Horizon for Breast Cancer: Managing Treatment-Emergent ToxicitiesПодробнее

Managing Pulmonary and Cardiac Adverse Events Related to ADC Therapy in Breast CancerПодробнее

Dr Bardia on Current Approaches to HER2+ Breast Cancer ManagementПодробнее

PROs from TROPION-Breast01: datopotamab deruxtecan in HR+/HER2- breast cancerПодробнее

Evaluating trastuzumab deruxtecan in earlier lines of breast cancer therapyПодробнее

REALITY-01: real-world use of trastuzumab deruxtecan in breast cancerПодробнее

Trastuzumab Deruxtecan FDA Approval and Future Directions for HER2-Positive Bladder CancerПодробнее

Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancerПодробнее